{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T12:07:27Z","timestamp":1789474047556,"version":"build-2803163510"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2025,2,22]],"date-time":"2025-02-22T00:00:00Z","timestamp":1740182400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,2,22]],"date-time":"2025-02-22T00:00:00Z","timestamp":1740182400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Nucl Med Mol Imaging"],"published-print":{"date-parts":[[2025,7]]},"DOI":"10.1007\/s00259-025-07154-w","type":"journal-article","created":{"date-parts":[[2025,2,22]],"date-time":"2025-02-22T02:51:22Z","timestamp":1740192682000},"page":"2856-2866","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Personalized baseline and residual TMTV influence treatment response and outcomes in relapsed\/refractory lymphomas: results from the GATA study"],"prefix":"10.1007","volume":"52","author":[{"given":"Sol\u00e8ne","family":"Malmon","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivier","family":"Casasnovas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marguerite","family":"Fournier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guillaume","family":"Cartron","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Salim","family":"Kanoun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne S\u00e9gol\u00e8ne","family":"Cottereau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles","family":"Herbaux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8104-9874","authenticated-orcid":false,"given":"Yassine","family":"Al Tabaa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,2,22]]},"reference":[{"issue":"1127","key":"7154_CR1","doi-asserted-by":"publisher","first-page":"20210448","DOI":"10.1259\/bjr.20210448","volume":"94","author":"M Meignan","year":"2021","unstructured":"Meignan M, Cottereau AS, Specht L, Mikhaeel NG. Total tumor burden in lymphoma - an evolving strong prognostic parameter. Br J Radiol. 2021;94(1127):20210448. https:\/\/doi.org\/10.1259\/bjr.20210448.","journal-title":"Br J Radiol"},{"issue":"16","key":"7154_CR2","doi-asserted-by":"publisher","first-page":"1396","DOI":"10.1182\/blood.2019003526","volume":"135","author":"L Vercellino","year":"2020","unstructured":"Vercellino L, Cottereau AS, Casasnovas O, Tilly H, Feugier P, Chartier L, et al. High total metabolic tumor volume at baseline predicts survival independent of response to therapy. Blood. 2020;135(16):1396\u2013405.","journal-title":"Blood"},{"key":"7154_CR3","doi-asserted-by":"publisher","first-page":"3618","DOI":"10.1200\/JCO.2016.66.9440","volume":"34","author":"M Meignan","year":"2016","unstructured":"Meignan M, Cottereau AS, Versari A, Chartier L, Dupuis J, Boussetta S, et al. Baseline metabolic tumor volume predicts outcome in High-Tumor-Burden follicular lymphoma: a pooled analysis of three multicenter studies. J Clin Oncol. 2016;34:3618\u201326. https:\/\/doi.org\/10.1200\/JCO.2016.66.9440.","journal-title":"J Clin Oncol"},{"issue":"4","key":"7154_CR4","doi-asserted-by":"publisher","first-page":"510","DOI":"10.2967\/jnumed.123.267022","volume":"65","author":"SF Barrington","year":"2024","unstructured":"Barrington SF, Cottereau AS, Zijlstra JM. Is (18)F-FDG metabolic tumor volume in Lymphoma really happening? Journal of nuclear medicine: official publication. Soc Nuclear Med. 2024;65(4):510\u20131.","journal-title":"Soc Nuclear Med"},{"issue":"3","key":"7154_CR5","doi-asserted-by":"publisher","first-page":"332","DOI":"10.2967\/jnumed.119.238923","volume":"62","author":"SF Barrington","year":"2021","unstructured":"Barrington SF, Zwezerijnen B, de Vet HCW, et al. Automated Segmentation of Baseline Metabolic Total Tumor Burden in diffuse large B-Cell lymphoma: which Method is most successful? A study on Behalf of the PETRA Consortium. Journal of nuclear medicine: official publication. Soc Nuclear Med. 2021;62(3):332\u20137.","journal-title":"Soc Nuclear Med"},{"issue":"9","key":"7154_CR6","doi-asserted-by":"publisher","first-page":"1343","DOI":"10.2967\/jnumed.124.267789","volume":"65","author":"R Boellaard","year":"2024","unstructured":"Boellaard R, Buvat I, Nioche C, Ceriani L, Cottereau AS, Guerra L, et al. International Benchmark for Total Metabolic Tumor Volume Measurement in baseline 18F-FDG PET\/CT of Lymphoma patients: a milestone toward clinical implementation. J Nucl Med. 2024;65(9):1343\u20138. https:\/\/doi.org\/10.2967\/jnumed.124.267789.","journal-title":"J Nucl Med"},{"issue":"2","key":"7154_CR7","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1007\/s00259-014-2961-x","volume":"42","author":"R Boellaard","year":"2015","unstructured":"Boellaard R, Delgado-Bolton R, Oyen WJ, et al. FDG PET\/CT: EANM procedure guidelines for tumour imaging: version 2.0. Eur J Nucl Med Mol Imaging. 2015;42(2):328\u201354.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"7","key":"7154_CR8","doi-asserted-by":"publisher","first-page":"1633","DOI":"10.3324\/haematol.2021.278663","volume":"107","author":"L Kostakoglu","year":"2022","unstructured":"Kostakoglu L, Mattiello F, Martelli M, et al. Total metabolic tumor volume as a survival predictor for patients with diffuse large B-cell lymphoma in the GOYA study. Haematologica. 2022;107(7):1633\u201342.","journal-title":"Haematologica"},{"issue":"21","key":"7154_CR9","doi-asserted-by":"publisher","first-page":"2489","DOI":"10.1182\/blood-2016-05-718528","volume":"128","author":"BD Cheson","year":"2016","unstructured":"Cheson BD, Ansell S, Schwartz L, et al. Refinement of the Lugano classification response criteria for lymphoma in the era of immunomodulatory therapy: the LYmphoma response to immunomodulatory therapy criteria (LYRIC). Blood. 2016;128(21):2489\u201396.","journal-title":"Blood"},{"issue":"27","key":"7154_CR10","doi-asserted-by":"publisher","first-page":"3048","DOI":"10.1200\/JCO.2013.53.5229","volume":"32","author":"SF Barrington","year":"2014","unstructured":"Barrington SF, Mikhaeel NG, Kostakoglu L, et al. Role of imaging in the staging and response assessment of lymphoma: consensus of the International Conference on Malignant Lymphomas Imaging Working Group. J Clin Oncol. 2014;32(27):3048\u201358.","journal-title":"J Clin Oncol"},{"issue":"20","key":"7154_CR11","doi-asserted-by":"publisher","first-page":"5222","DOI":"10.3390\/cancers13205222","volume":"13","author":"Y Al Tabaa","year":"2021","unstructured":"Al Tabaa Y, Bailly C, Kanoun S. FDG-PET\/CT in Lymphoma: where do we go now? Cancers (Basel). 2021;13(20):5222.","journal-title":"Cancers (Basel)"},{"key":"7154_CR12","first-page":"S234","volume":"295054","author":"C Herbaux","year":"2020","unstructured":"Herbaux C, Casasnovas O, Feugier P, et al. Efficacy and safety of atezolizumab\u2009+\u2009obinutuzumab\u2009+\u2009venetoclax in patients with relapsed or refractory diffuse large b-cell lymphomas: primary analysis of a phase 2 trial from lysa [abstract]. EHA Abstract. 2020;295054:S234.","journal-title":"EHA Abstract"},{"issue":"14","key":"7154_CR13","doi-asserted-by":"publisher","first-page":"3735","DOI":"10.1182\/bloodadvances.2023009911","volume":"7","author":"Y Al Tabaa","year":"2023","unstructured":"Al Tabaa Y, Casasnovas RO, Baillet C, et al. Prospective evaluation of lymphoma response to immunomodulatory therapy criteria in GATA trial from the LYSA group. Blood Adv. 2023;7(14):3735\u20137. https:\/\/doi.org\/10.1182\/bloodadvances.2023009911.","journal-title":"Blood Adv"},{"key":"7154_CR14","doi-asserted-by":"publisher","first-page":"1509","DOI":"10.1056\/NEJMoa0810780","volume":"360","author":"AM Cypess","year":"2009","unstructured":"Cypess AM, Lehman S, Williams G, Tal I, Rodman D, Goldfine AB, et al. Identification and importance of brown adipose tissue in adult humans. N Engl J Med. 2009;360:1509\u201317.","journal-title":"N Engl J Med"},{"issue":"10","key":"7154_CR15","doi-asserted-by":"publisher","first-page":"e0140830","DOI":"10.1371\/journal.pone.0140830","volume":"10","author":"S Kanoun","year":"2015","unstructured":"Kanoun S, Tal I, Berriolo-Riedinger A, Rossi C, Riedinger JM, Vrigneaud JM, et al. Influence of Software Tool and Methodological aspects of total metabolic tumor volume calculation on baseline [18F]FDG PET to Predict Survival in Hodgkin Lymphoma. PLoS ONE. 2015;10(10):e0140830.","journal-title":"PLoS ONE"},{"key":"7154_CR16","doi-asserted-by":"publisher","first-page":"1113","DOI":"10.1007\/s00259-014-2705-y","volume":"41","author":"M Meignan","year":"2014","unstructured":"Meignan M, Sasanelli M, Casasnovas RO, et al. Metabolic tumour volumes measured at staging in lymphoma: methodological evaluation on phantom experiments and patients. Eur J Nucl Med Mol Imaging. 2014;41:1113\u201322.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"7154_CR17","doi-asserted-by":"publisher","first-page":"3801","DOI":"10.1158\/1078-0432.CCR-15-2825","volume":"22","author":"AS Cottereau","year":"2016","unstructured":"Cottereau AS, Lanic H, Mareschal S, et al. Molecular profile and FDG-PET\/CT total metabolic tumor volume improve risk classification at diagnosis for patients with diffuse large B-cell lymphoma. Clin Cancer Res. 2016;22:3801\u20139.","journal-title":"Clin Cancer Res"},{"key":"7154_CR18","doi-asserted-by":"publisher","first-page":"1735","DOI":"10.1007\/s00259-014-2783-x","volume":"41","author":"S Kanoun","year":"2014","unstructured":"Kanoun S, Rossi C, Berriolo-Riedinger A, et al. Baseline metabolic tumour volume is an independent prognostic factor in Hodgkin lymphoma. Eur J Nucl Med Mol Imaging. 2014;41:1735\u201343.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"7154_CR19","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1093\/annonc\/mdw011","volume":"27","author":"AS Cottereau","year":"2016","unstructured":"Cottereau AS, Becker S, Broussais F, et al. Prognostic value of baseline total metabolic tumor volume (TMTV0) measured on FDG-PET\/CT in patients with peripheral T-cell lymphoma (PTCL). Ann Oncol. 2016;27:719\u201324.","journal-title":"Ann Oncol"},{"issue":"27","key":"7154_CR20","doi-asserted-by":"publisher","first-page":"3059","DOI":"10.1200\/JCO.2013.54.8800","volume":"32","author":"BD Cheson","year":"2014","unstructured":"Cheson BD, Fisher RI, Barrington SF, Cavalli F, Schwartz LH, Zucca E, et al. Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-hodgkin lymphoma: the Lugano classification. J Clin Oncol. 2014;32(27):3059\u201368.","journal-title":"J Clin Oncol"},{"issue":"12","key":"7154_CR21","doi-asserted-by":"publisher","first-page":"1857","DOI":"10.2967\/jnumed.110.080556","volume":"51","author":"E Itti","year":"2010","unstructured":"Itti E, Juweid ME, Haioun C, Yeddes I, Hamza-Maaloul F, El Bez I, et al. Improvement of early 18F-FDG PET interpretation in diffuse large B-cell lymphoma: importance of the reference background. J Nucl Med. 2010;51(12):1857\u201362.","journal-title":"J Nucl Med"},{"issue":"5","key":"7154_CR22","doi-asserted-by":"publisher","first-page":"677","DOI":"10.2967\/jnumed.112.108530","volume":"54","author":"RR Boktor","year":"2013","unstructured":"Boktor RR, Walker G, Stacey R, Gledhill S, Pitman AG. Reference range for intrapatient variability in blood-pool and liver SUV for 18F-FDG PET. J Nucl Med. 2013;54(5):677\u201382.","journal-title":"J Nucl Med"}],"container-title":["European Journal of Nuclear Medicine and Molecular Imaging"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-025-07154-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00259-025-07154-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-025-07154-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,12]],"date-time":"2025-06-12T05:23:03Z","timestamp":1749705783000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00259-025-07154-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,22]]},"references-count":22,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2025,7]]}},"alternative-id":["7154"],"URL":"https:\/\/doi.org\/10.1007\/s00259-025-07154-w","relation":{},"ISSN":["1619-7070","1619-7089"],"issn-type":[{"value":"1619-7070","type":"print"},{"value":"1619-7089","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,22]]},"assertion":[{"value":"18 December 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 February 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 February 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and\/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. GATA study has been realized in conformity with the Declaration of Helsinki, ICH-E6(R2) and French GCP. It has been approved by the French National Competent Authority (ANSM) and a National Ethics Committee (CPP Nord Ouest III). All patients received complete information and consented for their participation in the study and their data collection. LYSA Data Sharing Statement allows all data sharing after validation of the project by LYSA Scientific Board.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"The authors have no relevant financial or non-financial interests to disclose.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}